Clinical trial Recruiting at 1 site Observational Ages 19 and up

Long-Term Safety and Efficacy of Allogenic Umbilical Cord–Derived MSCs for Rotator Cuff Disease

Official title: A Single Center, Open Label, Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease

Run by Seoul National University Hospital · NCT07374679 · Data updated 2026-11-12

This long-term follow-up checks whether allogenic umbilical cord–derived mesenchymal stem cells are safe and helpful for people with rotator cuff disease who previously received the treatment.

More Rotator Cuff Tears trials

Quick facts

Study typeObservational
Ages19 Years and up
SexAll
Enrollment21 (estimated)
SponsorSeoul National University Hospital
Academic / other
Locations1 site (Seoul, Korea)
StatusRecruiting
StartedJanuary 27, 2026
Main results expectedMay 30, 2031
Study endsJanuary 30, 2032
Registry record updatedMay 22, 2026
Trial IDNCT07374679 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People who previously received the investigational MSC product in the Phase 1/2a trial (ASB-IP-001) and consented to long-term follow-up.

Probably not a fit

Patients with inability to be contacted or who face practical barriers to follow-up, or those deemed unsuitable by investigators due to safety risks or adherence concerns.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational follow-up study tracks patients who previously received an investigational allogenic umbilical cord–derived mesenchymal stem cell therapy for rotator cuff disease. It aims to gather long-term safety and efficacy data over time. Eligible participants include those from a prior Phase 1/2a trial who consented to continued monitoring. The study relies on routine follow-up assessments to monitor health status and any lasting effects. Enrollment is limited to sites at major Seoul medical centers in Korea.

Why it matters

Potential benefit: If successful, the study could clarify long-term safety and whether the therapy provides ongoing relief or functional benefits for rotator cuff disease.

How similar studies have gone: Prior similar studies have provided safety and durability data for stem cell therapies in musculoskeletal conditions, but long-term results for this specific product are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Subjects who received the investigational medicinal product in the Phase 1/2a clinical trial (ASB-IP-001).
* Subjects who voluntarily agreed to participate in this long-term follow-up study and provided written informed consent.

Exclusion Criteria:

* Subjects who cannot be contacted by any means, including telephone, mail, or e-mail, and for whom follow-up assessment is therefore not feasible.
* Subjects deemed inappropriate for participation in this long-term follow-up study at the investigator's discretion, including:

  * Cases in which participation in the study may pose a significant risk to the subject's health or safety; ② Cases in which long-term follow-up visits or assessments are practically impossible due to cognitive impairment, communication difficulties, or similar conditions; ③ Cases in which continued participation in follow-up is unlikely due to difficulty adhering to the study schedule (e.g., prolonged hospitalization, long-term residence abroad).

Where it's running

  • Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine
    Seoul, Korea, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.